Adverse drug reactions reported to the drug and poison information center of Tehran, Iran

PLoS ONE

Volumn 12, Issue 9, 2017, Pages

  Saheb Sharif Askari, Fatemeh ^a   Saheb Sharif Askari, Narjes ^a   Javadi, Mohammadreza ^a,b   Gholami, Kheirollah ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ATORVASTATIN; AZITHROMYCIN; CALCIUM CHANNEL BLOCKING AGENT; CONTRACEPTIVE AGENT; CORTICOSTEROID; CYPROTERONE ACETATE; GABAPENTIN; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOTRETINOIN; METFORMIN; METRONIDAZOLE; MINERAL; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RETINOIC ACID DERIVATIVE; SERTRALINE; VALPROIC ACID; VITAMIN;

ADOLESCENT; ADULT; AGE; AGED; APPARENT LIFE THREATENING EVENT; ARTICLE; BONE DISEASE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DISEASE BURDEN; DISEASE SEVERITY; DRUG INFORMATION; DRUG SAFETY; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GROUPS BY AGE; HEALTH CARE PERSONNEL; HOSPITALIZATION; HUMAN; HYPERSENSITIVITY; IRAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MIDDLE AGED; NEUROMUSCULAR DISEASE; NEWBORN; POISON CENTER; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; SEX; SEX DIFFERENCE; SKIN DISEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE; ADVERSE DRUG REACTION; CHILD; INFANT; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; IRAN; MALE; MIDDLE AGED; POISON CONTROL CENTERS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85029900928     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0185450     Document Type: Article

References (28)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279(15):1200–5. PMID: 9555760
2. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004; 329(7456):15–9. https://doi.org/10.1136/bmj.329.7456.15 PMID: 15231615
3. Wester K, Jönsson AK, Spigset O, Druid H, Hägg S. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol. 2008; 65(4):573–9. https://doi.org/10.1111/j.1365-2125.2007.03064.x PMID: 18070216
4. Shalviri G, Valadkhani M, Dinarvand R. Ten years pharmacovigilance activities in Iran. Iran J Public Health. 2009; 38(Suppl 1):162–5.
5. Egberts TC, Smulders M, De Koning FH, Meyboom RH, Leufkens HG. Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. BMJ. 1996; 313(7056):530–1. PMID: 8789980
6. Jarernsiripornkul N, Krska J, Capps P, Richards R, Lee A. Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol. 2002; 53(3):318–25. https://doi.org/10.1046/j.0306-5251.2001.01547.x PMID: 11874396
7. Grootheest K, Graaf L, Jong V, Berg L. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Netherlands Pharmacovigilance Centre Lareb,’s-Hertogenbosch. The Netherlands. 2003; 26(4).
8. Anderson C, Krska J, Murphy E, Avery A. The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective. Br J Clin Pharmacol. 2011; 72(5):806–22. https://doi.org/10.1111/j.1365-2125.2011.03990.x PMID: 21496066
9. Inácio P, Cavaco A, Airaksinen M. The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol. 2016.
10. Mey C, Hentschel H, Hippius M, Balogh A. Documentation and evaluation of adverse drug reactions (ADR)—contribution from a poison information center. Int J Clin Pharmacol Ther. 2002; 40(3):102–7. PMID: 11911597
11. Bencheikh RS, Benabdallah G. Medication errors: pharmacovigilance centres in detection and prevention. Br J Clin Pharmacol. 2009; 67(6):687–90. https://doi.org/10.1111/j.1365-2125.2009.03426.x PMID: 19594539
12. Hayes BD, Klein-Schwartz W, Gonzales LF. Causes of therapeutic errors in older adults: evaluation of National Poison Center data. J Am Geriatr Soc. 2009; 57(4):653–8. https://doi.org/10.1111/j.15325415.2008.02166.x PMID: 19220563
13. Cassidy N, Duggan E, Williams DJ, Tracey JA. The epidemiology and type of medication errors reported to the National Poisons Information Centre of Ireland. Clin Toxicol. 2011; 49(6):485–91.
14. Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med. 2008; 168(17):1890–6. https://doi.org/10.1001/archinternmed.2008.3 PMID: 18809816
15. Organization WH. International drug monitoring: the role of national centres, report of a WHO meeting [held in Geneva from 20 to 25 September 1971]. 1972.
16. Royal Pharmaceutical Society of Great B. British national formulary: BMJ Books; 2002.
17. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharm Ther. 1981; 30(2):239–45.
18. Pahor M, Chrischilles EA, Guralnik JM, Brown SL, Wallace RB, Carbonin P. Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol. 1994; 10(4):405–11. https://doi.org/10.1007/BF01719664 PMID: 7843344
19. Vassilev ZP, Chu AF, Ruck B, Adams EH, Marcus SM. Evaluation of adverse drug reactions reported to a poison control center between 2000 and 2007. Am J Health Syst Pharm. 2009; 66(5).
20. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Health Syst Pharm. 1992; 49(9):2229–32.
21. Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse drug events in the outpatient setting: an 11-year national analysis. Pharmacoepidemiology and drug safety. 2010; 19(9):901–10. https://doi.org/10.1002/pds.1984 PMID: 20623513
22. Sarkar U, López A, Maselli JH, Gonzales R. Adverse drug events in US adult ambulatory medical care. Health Serv Res. 2011; 46(5):1517–33. https://doi.org/10.1111/j.1475-6773.2011.01269.x PMID: 21554271
23. Mowry JB, Spyker DA, Brooks DE, McMillan N, Schauben JL. 2014 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 32nd Annual Report. Clin Toxicol. 2015; 53(10):962–1147.
24. Iran Census Results 2016. United Nations.
25. Field TS, Gurwitz JH, Avorn J, et al. RIsk factors for adverse drug events among nursing home residents. Arch Intern Med. 2001; 161(13):1629–34. https://doi.org/10.1001/archinte.161.13.1629 PMID: 11434795
26. Routledge PA, O’Mahony M, Woodhouse K. Adverse drug reactions in elderly patients. Br J Clin Pharmacol. 2004; 57(2):121–6. https://doi.org/10.1046/j.1365-2125.2003.01875.x PMID: 14748810
27. Hohl CM, Dankoff J, Colacone A, Afilalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med. 2001; 38(6):666–71. https://doi.org/10.1067/mem.2001.119456 PMID: 11719747
28. Smyth RMD, Gargon E, Kirkham J, Cresswell L, Golder S, Smyth R, et al. Adverse drug reactions in children - a systematic review. PLoS ONE. 2012; 7(3):e24061. https://doi.org/10.1371/journal.pone.0024061 PMID: 22403604